Charles Schwab
SKYE icon

Charles Schwab’s Skye Bioscience SKYE Stock Holding History

Charles Schwab’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-62,363
Closed -$99.2K – 3601
2025
Q1 		$99.2K Hold
62,363
– – ﹤0.01% 3344
2024
Q4 		$176K Buy
62,363
+10,707
+21% +$44.7K ﹤0.01% 3343
2024
Q3 		$202K Hold
51,656
– – ﹤0.01% 3337
2024
Q2 		$414K Buy
+51,656
New +$613K ﹤0.01% 3270

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Charles Schwab's SKYE Position: Q2 2025 in Review

Charles Schwab sold out of Skye Bioscience (SKYE) in Q2 2025, closing a stake of 62,363 shares — an estimated $99.2K sold.

Charles Schwab first reported a position in SKYE in Q2 2024 and held it in 4 quarters. The position peaked at $414K in Q2 2024. 58 funds tracked by Wall St. Rank hold SKYE as of Q2 2025.

  • Charles Schwab reported no remaining Skye Bioscience position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 62,363 Skye Bioscience shares in Q2 2025, an estimated $99.2K.
  • Charles Schwab first reported a position in Skye Bioscience in Q2 2024 and held it in 4 quarters.
  • Charles Schwab's Skye Bioscience position peaked at $414K in Q2 2024.
  • 58 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.